NATCOPHARM

NATCO PHARMA

Mid Cap BSE: 524816 NSE: NATCOPHARM
₹580.95
1.9 (0.33%)
As on 06 December, 2022 | 22:38

Natco Pharma Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in NATCO PHARMA

Start SIP

Natco Pharma Share Price

Natco Pharma Share Returns

  • Over 1 Month -7.16%
  • Over 3 Month -6.06%
  • Over 6 Month -16.72%
  • Over 1 Year -30.2%

Natco Pharma Key Statistics

P/E Ratio 26
PEG Ratio 0.4
Market Cap Cr 10,606
Price to Book Ratio 2.5
EPS 5.8
Dividend 1.1
Relative Strength Index 48.83
Money Flow Index 56.73
MACD Signal -8.88
Average True Range 14.62

Natco Pharma Investment Rating

  • Master Rating:
  • Natco Pharma has an operating revenue of Rs. 2,474.00 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 10% is healthy, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 11 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 129 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Natco Pharma Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 351806514530330394312
Operating Expenses Qtr Cr 281426552442281280235
Operating Profit Qtr Cr 70379-38884911476
Depreciation Qtr Cr 38373636343330
Interest Qtr Cr 2344322
Tax Qtr Cr 965-68-11616
Net Profit Qtr Cr 38308-6172547557

Natco Pharma Technicals

EMA & SMA

Current Price
580.95
1.9 (0.33%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 578.93
  • 50 Day
  • 594.53
  • 100 Day
  • 622.61
  • 200 Day
  • 679.59
  • 20 Day
  • 575.71
  • 50 Day
  • 594.28
  • 100 Day
  • 621.98
  • 200 Day
  • 686.23

Natco Pharma Resistance and Support

PIVOT
₹580.71
Resistance
First Resistance 584.4
Second Resistance 589.75
Third Resistance 593.46
RSI 48.83
MFI 56.73
MACD Single Line -8.88
MACD -6.55
Support
First Resistance 575.35
Second Resistance 571.65
Third Resistance 566.3

Natco Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 585,482 17,464,928 29.83
Week 460,845 22,332,568 48.46
1 Month 363,253 20,560,139 56.6
6 Month 372,604 21,175,098 56.83

Natco Pharma Result Highlights

Natco Pharma Synopsis

NSE-Medical-Diversified

Natco Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1767.80 Cr. and Equity Capital is Rs. 36.50 Cr. for the Year ended 31/03/2022. Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1981PLC003201 and registration number is 003201.
Market Cap 10,606
Sales 2,200
Shares in Float 9.31
No of funds 214
Yield 1.08
Book Value 2.54
U/D Vol ratio 0.6
LTDebt / Equity
Alpha -0.16
Beta 0.69

Natco Pharma

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 48.8%48.8%48.81%
Mutual Funds 7.63%6.75%7.39%
Insurance Companies 6.07%
Foreign Portfolio Investors 11.67%11.65%11.94%
Financial Institutions/ Banks 0.16%
Individual Investors 20.14%18.45%17.47%
Others 5.69%14.35%14.23%

Natco Pharma Management

Name Designation
Mr. V C Nannapaneni Managing Director
Mr. Rajeev Nannapaneni Director & CEO
Mr. T V Rao Independent Director
Mr. G S Murthy Chairman & Ind.Director
Mr. D G Prasad Independent Director
Dr. M U R Naidu Independent Director
Dr. Leela Digumarti Independent Director
Mr. P S R K Prasad Director & Exe. VP (Corp. Engg. Services)
Dr. Linga Rao Donthineni Director & President (Tech. Affairs)
Mr. Pavan Bhat Director

Natco Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Natco Pharma Corporate Action

Date Purpose Remarks
2022-11-10 Quarterly Results & 2nd Interim Dividend
2022-08-09 Quarterly Results & Interim Dividend
2022-05-30 Audited Results
2022-02-14 Quarterly Results & 3rd Interim Dividend
2021-11-11 Quarterly Results & Interim Dividend
Date Purpose Remarks
2022-11-22 INTERIM Re.0.75 per share (37.50%) Second Interim Dividend
2022-08-22 INTERIM Rs.3.50 per share(175%)Interim Dividend
2022-02-25 INTERIM Rs.2.00 per share (100%) Third Interim Dividend
2021-11-24 INTERIM Re.0.50 per share (25%) Second Interim Dividend
2021-08-25 INTERIM Rs.2.00 per share(100%)Interim Dividend

Natco Pharma MF Shareholding

Name Amount(cr)
ICICI Prudential Value Discovery Fund Growth 26750
Mirae Asset Emerging Bluechip Fund Growth 23691
Nippon India Small Cap Fund - Growth 22844
Mirae Asset Midcap Fund Regular Growth 8681
SBI Magnum Midcap Fund Regular Growth 8326

Natco Pharma FAQs

What is Share Price of Natco Pharma ?

Natco Pharma share price is ₹580 As on 06 December, 2022 | 22:24

What is the Market Cap of Natco Pharma ?

The Market Cap of Natco Pharma is ₹10605.7 Cr As on 06 December, 2022 | 22:24

What is the P/E ratio of Natco Pharma ?

The P/E ratio of Natco Pharma is 26 As on 06 December, 2022 | 22:24

What is the PB ratio of Natco Pharma ?

The PB ratio of Natco Pharma is 2.5 As on 06 December, 2022 | 22:24

Q2FY23